NEO (NeoGenomics Corp) שווי פירמה כולל

NeoGenomics, Inc. (NEO) serves pathologists, cancer centers, and drug developers who require precision tumor analysis. This price chart on GURU.Markets, where the enterprise value is 2447.09, links these markets to profit generators: genome sequencing and biomarker research. A mature management team has ensured the stability of business processes, with their authority validated by an expanding flow of diagnostic orders.

Enterprise Value represents the total acquisition cost of a business, combining market capitalization and net debt. For NeoGenomics, Inc. (NEO), this metric reflects the actual cost of acquiring assets that generate revenue from high-margin tumor sequencing. By analyzing the adjusted enterprise value, an investor can determine the actual entry price inclusive of all liabilities. The trend of this indicator helps identify the risk of overpaying for technological leadership. This is a key tool for assessing the fundamental attractiveness of the company.